PUBLISHED DATE: 18-Jan-17

Chemotherapy-induced Nausea and Vomiting (CINV) Market

Opportunities andForecasts, 2014- 2022

Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016, approximately 1.6 million new cases of cancer will be diagnosed with breast, lung, and bronchus cancer.

It is observed that approximately 35% of patients experienced nausea within 24 hours of chemotherapy, while 54% suffered from nausea and 34% experienced vomiting after 24 hours.

Growth in number of patients undergoing chemotherapy drugs treatment and introduction of new drug delivery methods to improve patient compliance are the major factors that significantly impact the growth of the CINV market.

At present, pharmaceutical companies are increasingly investing in the R&D of CINV drugs to offer better chemotherapy drugs and increase their market share.

The needle free, painless, and cost-effective transdermal delivery system is expected to witness increase in demand in global CINV market.

CINV MARKET-INTRODUCTION

CINV MARKET-KEY FINDINGS

The Aloxi segment generated highest

revenue in the global market in 2015,

accounting for over half of the total market.

The Netupitant-Palonosetron FDC segment is

the fastest growing segment at a CAGR of

10.8%.

TABLE OF CONTENTS

INTRODUCTION

EXECUTIVE SUMMARY

MARKET OVERVIEW

CINV MARKET BY PATIENT POOL

CINV MARKET BY GEOGRAPHY

COMPANY PROFILES

SEGMENT OVERVIEW-CINV MARKET

ASIA-PACIFIC CINV MARKET, 2014-2022 ($MILLION)

CINV MARKET- BY GEOGRAPHY

North America, Europe, Asia Pacific, LAMEA

1) GlaxoSmithKline plc

2) Helsinn Holding S.A

3) Heron Therapeutics

4) Merck & Co

5) Tesaro

COMPANY PROFILES

THANK YOU

Follow Us On

Thank You!For More Details

Visit us at https://www.alliedmarketresearch.com/cinv-market